0001209191-23-058061.txt : 20231211 0001209191-23-058061.hdr.sgml : 20231211 20231211163602 ACCESSION NUMBER: 0001209191-23-058061 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231207 FILED AS OF DATE: 20231211 DATE AS OF CHANGE: 20231211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eydelman Mikhail CENTRAL INDEX KEY: 0001918033 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 231478619 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 825 INDUSTRIAL ROAD, SUITE 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-07 0 0001649094 Vaxcyte, Inc. PCVX 0001918033 Eydelman Mikhail C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, SUITE 300 SAN CARLOS CA 94070 0 1 0 0 SVP, Gen Counsel & Corp Sec 1 Common Stock 2023-12-07 4 M 0 10000 21.41 A 31035 D Common Stock 2023-12-07 4 S 0 10000 56.50 D 21035 D Common Stock 2023-12-07 4 F 0 325 56.78 D 20710 D Stock Option (right to buy) 21.41 2023-12-07 4 M 0 10000 0.00 A 2032-05-08 Common Stock 10000 195000 D Includes 548 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Mikhail Eydelman, by /s/ Ron A. Metzger, Attorney-in-Fact 2023-12-11